Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Back to dashboard
Company Information
About this company
Key people
Russell John Howard
Independent Non-Executive Chairman of the Board
Marc Voigt
Chief Executive Officer, Executive Director
Deanne Miller
Chief Operating Officer, General Counsel, Joint Company Secretary
Frederic Triebel
Chief Scientific Officer, Executive Director
Christian Mueller
Chief Development Officer
Stephan Winckels
Chief Medical Officer
Indira Naidu
Joint Company Secretary
Lis Boyce
Non-Executive Director
Click to see more
Key facts
- Shares in issue73.69m
- EPICIMMP
- ISINUS45257L2079
- LocationAustralia
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$23.63m
- Employees-
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.